CClinicalTrials.gg
CompletedNCT02691429Updated Jun 7, 2017

Applicability of the Acai Fruit (Euterpe Oleracea) Dye for Chromovitrectomy in Humans

An interventional study of Acai dye 10% in Epiretinal Membrane, Macular Hole and Diabetic Retinopathy, sponsored by Federal University of São Paulo. Completed at 1 site in Brazil. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-06-07.

Sponsored by Federal University of São Paulo · Not applicable, Interventional, and Other

Phase
Not applicable
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Our research group tested the toxicity of different dye concentrations extracted from the acai fruit using a rabbit model. The dye extracted from the acai fruit in concentrations of 10% and 25% was found to be safe for vitreoretinal surgery. This initial research represented the landmark research for testing this alternative vital dye in a clinical research in humans.

The aim of the present clinical trial in humans will be to test the applicability of the acai dye in the identification of the posterior hyaloid and ILM during vitreoretinal surgery in humans.

Read the detailed description

The purpose of the present clinical trial in humans will be to test the impregnation capacity of the acai dye (10 and 25% concentrations) in the identification of the posterior hyaloid and ILM during vitreoretinal surgery in humans.

Twenty-four patients that seek treatment at the Ophthalmology Department of The Federal University of São Paulo will be selected for this study. Inclusion criteria will be patients diagnosed with epiretinal membrane, macular hole or diabetic retinopathy (with or without vitreal hemorrhages, and/or macular edema, and/or vitreomacular traction). All must be indicated for vitrectomy surgery for the removal of the epiretinal membrane and/or internal limiting membrane.

The present clinical trial was approved by the ethics committee of the Federal University of São Paulo (CEP-UNIFESP). All patients will be invited to sign an Informed Consent Form before participating in the study.

Twenty-four different retina surgeons will operate one of the 24 selected patients, using the standard vitrectomy technique that employs 4 sclerotomies and a 23-gauge system with accessory illumination. All surgeries will be performed using the acai dye (Euterpe oleracea) in the following concentrations: 10% (n=12) or 25% (n=12).

Immediately after the procedure, each surgeon will be given an evaluation questionnaire to fill-in.

All patients will be submitted to the following routine pre-operatory evaluations:

  1. Physical and pre-anesthesia evaluations - to be performed by the Anesthesiology Team of the São Paulo Hospital.
  2. Complete Ophthalmological Examination - that will include:

    1. Visual Acuity Measurements with best correction for both eyes.
    2. Applaination Tonometry (Goldman Tonometer). For this, one drop of anesthetic solution and one drop of fluorescein were instilled in the eye.
    3. Biomicroscopy
    4. Indirect binocular ophthalmoscopy: under mydriasis that will be obtained before each procedure by topical application of tropicamide and phenylephrine.
    5. Retinography and Angiofluoresceinography (with patient under mydriasis- except when "opacidade de meios")
    6. Optical Coherence Tomography (OCT) of the posterior segment (except when "opacidade de meios")
    7. Multifocal Electroretinogram (except when "opacidade de meios")

The vitrectomy surgery will be performed in all patients of this present study using the 23-gauge technique composed of 4 sclerectomies and vitrectomy without 23-gauge sutures.

During surgery, after vitreous removal, the dye extracted from the acai fruit will be slowly injected using a 23 or 25-gauge silicone cannula connected to a 5ml syringe. The objective of the slow injection of the dye is so that it will deposit over the posterior hyloid/peripheral vitreous due to gravity. At this moment, photographic documentation will be performed.

After the dislocation of the posterior hyloid, the removal of the peripheral vitreous and the excess dye, a MachemerTM (Volk, Germany) macula magnifying lens will be used to improve visualization for the removal of the ILM using an intraocular tweezers. If the ILM is not visible, a second injection with the dye will be performed.

At the end of the surgery, all patients will receive medical prescription of drops with antibiotic and corticoid association during 1 week after the procedure, following vitrectomy post-surgical routine.

A questionnaire with 6 questions (ANNEX 1) will be handed to each surgeon after the end of the surgery.

02

Conditions studied

  • Epiretinal Membrane
  • Macular Hole
  • Diabetic Retinopathy

Keywords

  • Vitreoretinal surgery
  • euterpe oleracea
  • chromovitrectomy
03

In context

Diabetic Retinopathy

773 studies on the registry are indexed under Diabetic Retinopathy; 139 are open to participants now.

This study's planned enrollment of 24 is below the median of 78 across 480 interventional studies indexed under Diabetic Retinopathy.

Browse Diabetic Retinopathy studies →

Lead sponsor

Federal University of São Paulo is the lead sponsor of 427 studies on the registry; 22 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Diagnosed with epiretinal membrane, macular hole or proliferative diabetic retinopathy (with or without vitreous hemorrhage).
  • Indicated for surgical removal of the epiretinal memebrane (with or without removal of the internal limiting membrane).

Exclusion criteria

Exclusion Criteria:

    • Previous ocular pathology
  • Glaucoma
  • Any other previous ocular infection that would modify ocular anatomy.
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
24 participants (estimated)

Study arms

  • Active comparator
    acai dye (Euterpe oleracea) 10%

    Twenty-four different retina surgeons will operate one of the 24 selected patients, using the standard vitrectomy technique that employs 4 sclerotomies and a 23-gauge system with accessory illumination. All surgeries will be performed using the acai dye (Euterpe oleracea) in the following concentrations: 10% (n=12) or 25% (n=12). Immediately after the procedure, each surgeon will be given an evaluation questionnaire to fill-in

    Other: Acai dye 10%

  • Active comparator
    acai dye (Euterpe oleracea) 25%

    Twenty-four different retina surgeons will operate one of the 24 selected patients, using the standard vitrectomy technique that employs 4 sclerotomies and a 23-gauge system with accessory illumination. All surgeries will be performed using the acai dye (Euterpe oleracea) in the following concentrations: 10% (n=12) or 25% (n=12). Immediately after the procedure, each surgeon will be given an evaluation questionnaire to fill-in

    Other: Acai dye 10%

Interventions

  • OtherAcai dye 10%

    dye to be used during chromovitrectomy in humans

    Also known as: euterpe oleracea dye

06

What researchers measure

Primary outcomes

  1. ocular inflammation

    signs of ocular inflammation

    Time frame: up to 30 days

Secondary outcomes

  1. intraocular pressure

    increase of intraocular pressure

    Time frame: up to 30 days

  2. complications of the posterior segment

    macular edema

    Time frame: up to 30 days

07

Study locations

1 site
  • Dept of Ophthalmology - UNIFESP/Hospital São Paulo
    São Paulo, SP 04023-062, Brazil
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 7, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02691429
Lead sponsor
Federal University of São Paulo
Collaborators
Rafael R. Caiado, Casa de Saúde São José, Acácio Alves Souza Lima-Filho, Eduardo Novais, Emmerson Badaró, André Maia, Rita Sinigaglia-Coimbra, Sung Eun S. Watanabe, Eduardo B. Rodrigues, Michel Eid Farah, Mauricio Maia
Responsible party
Mauricio Maia (MD, PhD, Federal University of São Paulo) — Principal investigator
First posted
Feb 25, 2016
Start date
Feb 2016
Primary completion
Nov 2016
Completion
May 2017
Last update
Jun 7, 2017

Study contacts

Mauricio Maia
principal investigator · Federal University of São Paulo UNIFESP

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion